Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."
Damian Finio
CFO
Recent News
Teligent Regains Compliance with NASDAQ Listing Requirements
BUENA, N.J. , June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jerse...
Teligent Announces Conversion Rate Adjustment for its 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes Due 2023 and its 4.75% Convertible Senior Notes Due 2023
BUENA, N.J. , June 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jerse...
